Daily Journal
Avatar de Nathan C. Frey

Nathan C. Frey

@nc_frey

Head of Drug Discovery & Development Research @AnthropicAI | previously CTO & Co-Founder @CoefficientBio (acq. by @AnthropicAI) | ex-@Genentech | @MIT @Penn

13 postsÚltimo em 9 de nov, 17:32Atualiza a cada 15 min

  1. Abrir

    With this model release, Claude is beginning to feel like a very capable assistant for research. One exercise I can recommend is sharing an older paper or draft, and asking the model to reimplement or extend it in some way. Claude Mythos 5.2 excels on long-horizon research tasks. I ask all our models to hypothesize about the function of vault particles now. Here’s what Mythos 5.2 thinks:

    Claude@claudeai

    Introducing Claude Fable 5.2 and Claude Mythos 5.2, designed to tackle the most daunting technical challenges. They’re capable collaborators on ambitious projects in many fields, and show improvements in areas like coding, reasoning, and vision.

  2. Abrir

    Vault particles are in most cells in your body and they're still a big mystery. Our biology research team showed that vault proteins from bacteria and their phages assemble into real vaults that are bigger than human vaults. They solved the first structure of one, from a bacteriophage.

    Anthropic@AnthropicAI

    We’re sharing how our biology research team worked with Claude to map the first 3D structure of a vault particle from bacterial life. Vault particles are a longstanding mystery. They are barrel-shaped objects, among the largest protein structures found in our cells. They were first discovered by Leonard Rome and Nancy Kedersha in 1986, but their function remains unknown. With Claude, we’ve found results that might bring us closer to solving that mystery. Until now, vaults were only known in the cells of complex things like animals and plants. We have shown that similar proteins from bacteria (and the viruses that infect them) can also assemble into vaults. Finding the structures in these simpler forms of life may make it easier to investigate their function in our own cells. For our life sciences team, the project was also a demonstration of the potential (and the limitations) of using AI to accelerate science. In our full piece, we discuss how Claude was able to dramatically speed up some stages—manually determining the vault particle’s structure would have taken weeks to months of painstaking work, but here it took days. We also discuss how Claude made some simple mistakes along the way, and how we collaborated with our machine learning researchers to address them. Read more: t.co/KowVVCSPp8

  3. Abrir
    Resposta

    @SynBio1 open.spotify.com/track/0eVz3hV2…

  4. Abrir
    Resposta

    @gline @ArmstrongDrew I loved your interview with @matthewherper and your quote - it's an unofficial motto for our team now.

  5. Abrir

    hey! wait! don't go out! it's unsafe! biotech is a woodchipper built to ingest souls and shred them! you need your own pipeline-in-a-person for your protection.

    Professor Oak@Prof_Oak_

    Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All

  6. Abrir

    The best way to identify and work through the bottlenecks of drug development is to get deeply involved in real drug programs, across many different therapeutic areas and stages of development. Over the past several months, our scientists have engaged in deep research partnerships with six organizations developing new medicines: The Column Group, Generate Biomedicines, BigHat Biosciences, Divergence Labs, Enveda, and Bristol Myers Squibb. We’ve also begun our own drug discovery efforts through the acquisition of Mithril Medicine, a single-person biotech company co-founded by @atlasventure. Today we’re sharing early progress in accelerating drug discovery from these research collaborations. With Claude, we are streamlining operations and working to derisk novel targets with TCG, redesigning lab protocols with BigHat, designing CAR-T cell therapies with Generate, and multi-specific therapeutic antibodies with Divergence, drafting regulatory filings with Enveda, and supporting portfolio-level decision making with BMS. Our early collaborations span pre-clinical and clinical work on potential treatments for cancer, allergies, rare genetic diseases including forms of childhood muscular dystrophy, and more. My team has been working with @Prof_Oak_ , founder of Mithril Medicine, for the past year. Jason Rhodes, General Partner @atlasventure and Chairman of the Mithril Board said this about Mithril: “We prioritized LAMA2-Related Congenital Muscular Dystrophy (LAMA2-RD) as the lead indication, in part, because of the enormous unmet need. These patients present with the disease at birth, spend their lives in wheelchairs and on ventilators, and rarely live past their mid-twenties; yet no therapy is available, and few are in active development. We believed Mithril would be the company to change that.” Anthropic acquired Mithril and we are pushing the frontier of how a single skilled operator, with Claude, can run an entire pipeline of drugs. We’re working with these teams to show how AI can assist drug developers at many stages of the process already, and to prioritize improvements to our models based on the benchmarks we’re building with collaborators. Our blog includes links to technical reports written with our partners: t.co/xGG6tJGMPJ

  7. Abrir

    Today, we’re announcing an open call for guest investigators in life sciences. Over 8–12 weeks, guest investigators will work directly with my team and other Anthropic researchers to produce analyses and tools for their work. We’ll run our models and harnesses, at no cost to them. We’ll work together to open-source the resulting data, artifacts, and code, and write preprints about what we find. We want humans to remain at the center of scientific discovery, deciding what questions to pursue, and how to pursue them. Those decisions are not ours to make alone. This open call is part of our ongoing efforts at Anthropic to support researchers and accelerate scientific discovery. I’m looking for principal investigators and their research groups at academic institutions, nonprofits, or government labs, working in causal human biology, structural and computational molecular biology, medicinal chemistry, drug discovery, and clinical science. Applications are open for about 14 days: t.co/bCcrKjB3W7

  8. Abrir

    Where do you go next after reporting from the Strait of Hormuz? For the past three months, Citrini Research, an independent research firm, has been working with our team and an internal research model to see if they could use AI to create a new drug. What follows is an entertaining, candid, and humbling account of a group of motivated nonexperts (or “filthy casuals”, as Citrini would say) trying to tackle a real problem in human health with Claude. We landed on scorpion neurotoxins, which kill over 3,000 people a year. Of the 211 designs we produced and tested, 17 met our criteria for a binder. None of the designs bound more than one toxin and none have been tested for neutralizing a toxin. One of my favorite quotes from the piece is: “Our virtual biologist may have compressed a year's worth of work into a couple days, but biology works at the speed of life…Over two days, we watched Claude work through problems at a speed that was difficult to comprehend. For the next two months, we spent much of the time becoming familiar with laboratory turnaround times (This mostly involved sending memes in Slack).”

    Citrini@citrini

    What is AI really capable of in bio? To separate hype from reality, we spent 3 months working firsthand with @AnthropicAI's internal research model to see if it could create an experimental scorpion antivenom. Introducing Citrini Therapeutics. citriniresearch.com/p/citrini-ther…

  9. Abrir

    Join us for four months at Anthropic as a STEM fellow. You'll work directly with our research team on ambitious, open-ended problems in your field of expertise. I encourage you to apply even if you don't think you meet every single qualification. job-boards.greenhouse.io/anthropic/jobs…

  10. Abrir

    "Our experiments suggest that small AI models may be months away from being capable enough to self-replicate on commercial IoT devices, like smart ovens and off-brand Android TV boxes. A replicator like this would be challenging to shut down, since there’s no centralized point to shut off - though it may be slow (with a doubling time of days)...Models of 30B parameters and under can already complete many of the individual steps for replication today, though they make mistakes when composing them end to end. In our simplified evals, GLM-5.2 and stronger models are capable of end to end replication. If small models improve at their historical rate, they’ll match this capability level by the end of this year." t.co/LVygrLjPRO

  11. Abrir

    We're committing $150M to the Genesis Mission to support American scientific research. The funding will help get Claude to more than 15 agencies, including NASA, NIH, NSF, and to scientists across the national labs. anthropic.com/news/genesis-m…

  12. Abrir

    Here is our first protein design challenge! We're ramping up the difficulty by asking for cross-reactivity and pH-dependence for selective binding in the tumor microenvironment. This is a step towards demonstrating more therapeutically relevant capabilities. Our role, in partnership with Adaptyv, is to provide lots of Claude, compute, and budget to test designs in the lab, so the best protein designers in the world can go after this problem with their favorite models.

    Amir Shanehsazzadeh@amirshanehsaz

    We're excited to be unveiling the first challenge in our protein design competition! EGFR is the target from the first competition, but we're asking for much more this time: a mouse cross-reactive binder that conditionally binds at acidic pH but not neutral pH. This problem is at the frontier of today's capabilities, but I'm confident that the world's leading designers, equipped with a ton of tokens and compute, and over 1,000 designs screened in the lab will be able to solve it.

  13. Abrir

    Claude Opus 5.5 dreams of biology. Claude made this with 30 lines of JavaScript on an HTML canvas. no image models involved. it's all code.

Posts exibidos como publicados originalmente em @nc_frey. Links encurtados e mídia ficam disponíveis ao abrir o post no X.